Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7991234 | 0.98 | ALDH1A1 (0.47) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL11241473 | 0.98 | ALDH1A1 (0.47) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL7991295 | 0.98 | ALDH1A1 (0.47) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL724520 | 0.94 | ALDH1A1 (0.47) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL316396 | 0.93 | — | — | |
| SCHEMBL60610 | 0.92 | ALDH1A1 (0.46) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL11236833 | 0.92 | ALDH1A1 (0.46) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL61669 | 0.92 | ALDH1A1 (0.46) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL11236830 | 0.92 | ALDH1A1 (0.46) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL6839659 | 0.92 | ALDH1A1 (0.46) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352321-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | claimed |
| EP-3154956-A1 | GLUCAGON ANTAGONISTS | Ligand Pharmaceuticals, Inc. (US) | 2017-04-19 | — | — | EP | claimed |
| WO-2015191900-A1 | GLUCAGON ANTAGONISTS | LIGAND PHARMACEUTICALS, INC. (US) | 2015-12-17 | — | — | WO | claimed |
| EP-2046147-B1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2013-05-01 | — | — | EP | claimed |
| JP-2012500212-A | — | — | 2012-01-05 | — | — | JP | claimed |
| EP-2326618-A1 | GLUCAGON ANTAGONISTS | Metabasis Therapeutics, Inc. (US) | 2011-06-01 | — | — | EP | claimed |
| WO-2010019830-A1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | WO | claimed |
| US-20090311403-A1 | Method of Using Organic Compounds | GIVAUDAN SA (CH) | 2009-12-17 | — | — | US | claimed |
| EP-2046147-A1 | METHOD OF USING ORGANIC COMPOUNDS | Givaudan SA (CH) | 2009-04-15 | — | — | EP | claimed |
| WO-2008011742-A1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-01-31 | — | — | WO | claimed |
| EP-0227241-B1 | Medicinal indole and indazole keto sulphone derivatives | ZENECA INC (US) | 1996-09-11 | — | — | EP | claimed |
| US-5234942-A | Treating allergic pulmonary disorders, asthma | ICI AMERICAS INC. (US) | 1993-08-10 | — | — | US | claimed |
| EP-0242167-B1 | HETEROCYCLIC CARBOXAMIDES | ICI AMERICAS INC. (US) | 1991-11-27 | — | — | EP | claimed |
| US-4997844-A | Compounds for the treatment of allergic or inflammatory diseases or shock conditions | ICI AMERICAS INC. (US) | 1991-03-05 | — | — | US | claimed |
| EP-0179619-B1 | HETEROCYCLIC AMIDES | ICI AMERICAS INC. (US) | 1990-09-05 | — | — | EP | claimed |
| US-4898863-A | Heterocyclic carboxamides | ICI AMERICAS INC. (US) | 1990-02-06 | — | — | US | claimed |
| US-4837235-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | ICI AMERICAS INC. (US) | 1989-06-06 | — | — | US | claimed |
| EP-0242167-A2 | Heterocyclic carboxamides | ICI AMERICAS INC. (US) | 1987-10-21 | — | — | EP | claimed |
| EP-0227241-A2 | Medicinal indole and indazole keto sulphone derivatives | ZENECA INC. (US) | 1987-07-01 | — | — | EP | claimed |
| US-3987069-A | BORON PHOSPHATE CATALYST | PETRO-TEX CHEMICAL CORPORATION (US) | 1976-10-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311403-A1 | Method of Using Organic Compounds | MGLL, GK, LIPC | ALDH1A1 788/4885ALOX15 448/4885PKM 310/4885 |
| US-11352321-B2 | Glucagon antagonists | GLP1R, GCG, GCGR | ALDH1A1 3771/4885ALOX15 3383/4885PKM 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.